Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells.
Dendritic cells (DCs) are required for the initiation of primary immune responses. The pattern of Toll-like receptor (TLR) expression on various subsets of these cells has been shown to differ, suggestive of distinct roles in influencing immune responses. We have examined here the responses of immature DCs derived from murine bone marrow (BMDCs) to a range of TLR ligands. BMDCs cultured for 6 days in the presence of granulocyte-macrophage colony-stimulating factor were stimulated for 24 hr with ligands to TLR1-2 [Pam(3)Cys-Ser-(Lys)(4) (PAM)], TLR2-6 (macrophage-activating lipopeptide-2 (MALP-2); zymosan or peptidoglycan (PG)], TLR3 (polyinosinic-polycytidylic acid), TLR4 [lipopolysaccharide R515 (LPS)], TLR5 (flagellin), TLR7 (polyuridylic acid) and TLR9 [CpG ODN2395 (CpG)]. DC activation was monitored using membrane marker expression and analysis of culture supernatants for cytokine/chemokine release. Ligands to TLR3 and TLR7 failed to activate BMDCs. All other TLR ligands caused elevated expression of membrane markers. PAM, MALP-2 and LPS induced high-level expression of proinflammatory cytokines and chemokines. Treatment with CpG was associated with a preferential type 1 cytokine and chemokine profile. Zymosan and PG were proinflammatory but also skewed towards a type 2 pattern of cytokines and chemokines. In contrast, flagellin did not cause marked secretion by BMDCs of cytokines or chemokines. These data for BMDCs are largely consistent with the reported TLR repertoire of freshly isolated murine Langerhans cells. In addition, murine BMDCs show selective responses to TLR ligands with respect to general activation, with differentiated cytokine patterns suggestive of potential priming for divergent immune responses.
Dearman
Rebecca J
RJ
Faculty of Life Sciences, University of Manchester, Manchester, UK. rebecca.dearman@manchester.ac.uk
Cumberbatch
Marie
M
Maxwell
Gavin
G
Basketter
David A
DA
Kimber
Ian
I
D000818:Animals; D001854:Bone Marrow Cells / Q000276:immunology; D002454:Cell Differentiation / Q000276:immunology; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D016130:Immunophenotyping; D008024:Ligands; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D051193:Toll-Like Receptors / Q000378:metabolism*
D016207:Cytokines; D008024:Ligands; D008070:Lipopolysaccharides; D051193:Toll-Like Receptors
J Immunol. 2004 Aug 15;173(4):2780-91
15294997
Biochem Biophys Res Commun. 2003 Jul 4;306(3):674-9
12810071
J Immunol Methods. 1999 Feb 1;223(1):77-92
10037236
J Immunol. 1998 Feb 15;160(4):1666-76
9469423
J Immunol. 2006 Dec 1;177(11):7959-67
17114468
J Immunol. 2000 May 15;164(10):5113-9
10799868
Nat Rev Immunol. 2006 Jan;6(1):33-43
16341139
J Immunol. 2007 Nov 1;179(9):5811-8
17947654
Immunology. 2008 Jul;124(3):329-38
18194273
Antimicrob Agents Chemother. 2005 Oct;49(10):3991-6
16189071
Mol Immunol. 2007 Mar;44(7):1483-9
17052755
J Immunol. 2003 May 15;170(10):5165-75
12734364
Scand J Immunol. 2000 Jun;51(6):586-94
10849369
Int Immunol. 2002 May;14(5):433-44
11978773
Infect Immun. 2003 Jun;71(6):3337-42
12761116
Nat Immunol. 2006 Aug;7(8):868-74
16829963
J Immunol. 2003 Apr 15;170(8):4102-10
12682240
Semin Immunol. 2004 Feb;16(1):27-34
14751761
Trends Immunol. 2006 Mar;27(3):132-9
16458606
Annu Rev Immunol. 1991;9:271-96
1910679
Infect Immun. 2005 Oct;73(10):6763-70
16177354
J Biol Chem. 2001 Oct 5;276(40):37692-9
11477091
Infect Immun. 2002 Dec;70(12):6638-45
12438336
J Leukoc Biol. 2005 Oct;78(4):888-97
16033815
Curr Mol Med. 2003 Dec;3(8):759-71
14682496
Toxicol In Vitro. 2004 Apr;18(2):195-202
14757110
J Exp Med. 1992 Dec 1;176(6):1693-702
1460426
Immunology. 2006 Jun;118(2):250-6
16771860
J Immunol. 2007 Nov 15;179(10):6830-5
17982073
J Immunol. 2006 Dec 1;177(11):7551-8
17114424
Eur J Immunol. 2004 Mar;34(3):899-907
14991620
J Invest Dermatol. 2005 Feb;124(2):343-50
15675953
Immunity. 2005 Dec;23(6):611-20
16356859
Nature. 1992 Nov 19;360(6401):258-61
1279441
J Invest Dermatol. 2004 Jan;122(1):95-102
14962096
Semin Immunol. 2005 Aug;17(4):273-83
15953735
J Immunol. 2004 Mar 1;172(5):2739-43
14978071
Biochem Biophys Res Commun. 2004 Jul 2;319(3):832-9
15184058
Immunol Res. 2006;36(1-3):127-36
17337773
J Immunol. 2001 Nov 1;167(9):5067-76
11673516
J Immunol. 2006 Jul 1;177(1):298-305
16785525
Science. 2004 Mar 5;303(5663):1529-31
14976261
J Immunol. 2007 Feb 15;178(4):1986-90
17277101
Biochem Biophys Res Commun. 2007 Oct 5;361(4):1012-6
17679142
Cell Immunol. 2007 Feb;245(2):70-9
17507001
J Immunol Methods. 1996 Sep 27;196(2):121-35
8841451
J Immunol. 2000 Dec 15;165(12):6743-7
11120793
J Immunol. 2003 Nov 15;171(10):4984-9
14607893
J Immunol. 2005 Oct 15;175(8):5146-51
16210618
J Biol Chem. 2006 Oct 13;281(41):31002-11
16880211
J Cell Biol. 2005 May 23;169(4):569-76
15897263
J Immunol. 2004 Jun 1;172(11):6922-30
15153511